Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Africa, alpha, alter, amyotrophic, antagonist, attack, Barrington, bilateral, book, Britain, budget, CapesarisTM, career, catabolic, category, children, China, chose, commitment, compatible, concomitant, conventional, curtail, Decapeptyl, degarelix, descend, discount, discounted, Doctor, Dodson, Domingo, Dominican, donut, DXA, East, EMA, Endo, epithelial, ER, estradiol, exceeded, exceeding, excretion, family, FARESTON®in, FDAAA, feasible, Ferring, Firmagon, follicle, France, Furr, gap, gene, globulin, Great, Histerlin, histrelin, hole, hypothalamic, Ib, implant, incapable, injection, input, intolerant, Leader, leg, lesser, Liaison, lieu, machine, malignancy, Mercer, mid, Middle, myasthenia, Nashville, nausea, neurological, neutropenia, nonselective, ofFARESTON®to, osteoporotic, overbroad, pamoate, pausing, Pharm, poor, pursuit, QLT, Reconciliation, reestablished, refractory, renegotiate, Republic, residency, resistant, respiratory, Revatio, Rodriguez, rural, Science, Scientist, SHBG, Shontelle, solid, Southern, Spain, stage, symptom, syndrome, therapeutic, TM, Trelstar, triptorelin, viable, Viagra, viewed, XgevaTM
Removed:
abnormal, accelerate, accurate, acid, aggravation, agree, alendronate, amending, American, analyzed, androgenic, andropause, anguish, annualized, biopsy, bisphosphonate, blinded, blocking, bulk, burn, cancel, chemotherapy, clonidine, comprising, computing, concentrated, congressional, contrast, correlation, created, damaged, desire, detecting, DEXA, diagnostic, digital, directly, discomfort, dispute, documented, dominant, DSMB, easily, efficiency, eligibility, endurance, energy, enrolled, expiring, facial, FARESTON®to, fatigued, fearing, forecast, foregoing, frail, fuel, graduating, greatly, harbor, holding, Hollow, hope, hydrochloride, imminent, imply, infection, inhibitor, inserted, intact, invasive, involuntary, Kingdom, legitimate, live, long, main, Marinol, masculinizing, maximize, metabolism, metabolizing, mineralization, minimize, missed, Monitoring, monthly, myocardial, needle, network, notably, nuclear, ocular, onset, partnered, passed, people, pharmacological, pound, predefined, preferential, probe, properly, protein, purport, pursuing, randomly, reach, rectal, rectum, recycle, rehabilitate, relying, repair, repeat, replenish, requested, revert, revised, risendronate, routinely, sample, sedentary, separate, shortfall, show, shrinking, significance, similarly, sodium, SPA, speed, sponsored, statistical, stratified, subgroup, suitable, technique, thin, threshold, topical, Treasurer, typical, ultimately, ultrasound, unblinded, undiagnosed, unintentional, unknowingly, unselective, unstratified, upstream, urine, venlafaxine, world, worsen, zoledronic
Filing tables
Filing exhibits
Related press release
ONCT similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-118882) pertaining to the GTx, Inc. Directors’ Deferred Compensation Plan, |
(2) | Registration Statement (Form S-8 No. 333-112576) pertaining to the GTx, Inc. 2004 Equity Incentive Plan, 2004 Non-Employee Directors’ Stock Option Plan, 2002 Stock Option Plan, 2001 Stock Option Plan, 2000 Stock Option Plan, and 1999 Stock Option Plan, |
(3) | Registration Statement (Form S-8 No. 333-136527) pertaining to the GTx, Inc. Amended and Restated 2004 Non-Employee Directors’ Stock Option Plan, |
(4) | Registration Statements (Form S-8 Nos. 333-149661 and 333-165507) pertaining to the GTx, Inc. 2004 Equity Incentive Plan and the Amended and Restated 2004 Non-Employee Directors’ Stock Option Plan; |
of our reports dated March 8, 2011, with respect to the financial statements of GTx, Inc. and with respect to the effectiveness of internal control over financial reporting of GTx, Inc., included in this Annual Report (Form 10-K) of GTx, Inc. for the year ended December 31, 2010.
/s/ Ernst & Young LLP
Memphis, Tennessee
March 8, 2011
Memphis, Tennessee
March 8, 2011